Anti-Inflammatory Compounds Blocking IL-4Rα Cytokine Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic approaches for inflammatory skin conditions, such as atopic dermatitis, fail to effectively modulate the interaction between IL-4 and IL-13 with IL-4Rα, leading to unmet needs in managing chronic inflammation and symptoms like redness and dryness.
Innovation Solution
Administering compounds with specific chemical structures, such as Formula (I) to (V), which inhibit or reduce the interaction between IL-4 and IL-13 with IL-4Rα, thereby decreasing their expression in activated Th2 cells and blocking their engagement with the receptor complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic approaches are used for inflammatory skin conditions, then treatment is provided, but they fail to effectively modulate the interaction between IL-4 and IL-13 with IL-4Rα, resulting in insufficient relief of chronic inflammation and symptoms
Solution Approach 1:
The patent employs small molecule compounds with specific chemical structures (Formulas I-V) that bind to IL-4Rα, changing the binding parameters and preventing IL-4 and IL-13 from interacting with the receptor. This parameter change in molecular interaction directly addresses the insufficiency of conventional therapies in modulating the cytokine-receptor interaction
Solution Approach 2:
The small molecule compounds act as intermediaries between IL-4/IL-13 and IL-4Rα, blocking the direct interaction between these cytokines and their receptor. These intermediary molecules prevent the harmful signaling pathway while allowing the use of specific chemical structures to achieve targeted inhibition
2Ease of operation
If existing therapies are administered, then some symptom relief is provided, but they do not adequately address the complex pathophysiology including epidermal barrier dysfunction, IgE sensitization, and immune dysregulation
Solution Approach 1:
The patent takes preliminary action by blocking the IL-4/IL-13 signaling pathway at its origin through small molecule inhibition of IL-4Rα binding. This upstream intervention prevents the downstream effects that lead to epidermal barrier dysfunction and other pathological changes, addressing the complex pathophysiology before it fully develops
Solution Approach 2:
By changing the molecular binding parameters between cytokines and receptors, the invention achieves comprehensive disease management that addresses multiple aspects of the pathophysiology simultaneously, including immune dysregulation and barrier dysfunction, rather than treating individual symptoms in isolation
Data Source
AI summary
Compounds and compositions for relief, management, or treatment of inflammation conditions, disorders, or diseases are provided herein. Methods for treatment of inflammatory conditions or disorders are also provided herein. The methods may reduce dryness, itching, redness, roughness, or flakiness of skin.